BioSpace News Archive

The Government of Canada is closely monitoring the genetic variant of the virus that causes COVID-19 identified in the United Kingdom and is working with international and other partners including the World Health Organization to better understand this variant and its impacts.

COMIRNATY ® (also known as BNT162b2) receives conditional marketing authorization from the European Commission; this milestone represents a global joint effort to advance the first authorized mRNA vaccine

SCONE Medical Solutions Inc., a Phoenix -based MedTech startup, has pioneered a new strategy for PPE in healthcare facilities, aimed at reducing the risk of aerosol transmission of contagious diseases to healthcare workers (HCWs), other patients, and hospital visitors. The Self-Contained Negative Pressure Environment (SCONE™) is a low-c

Mulberry Health Inc., d/b/a Oscar, announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to its proposed initial public offering of its common stock.

LeAnn Affholter, Vice President of People, and Carla Pagotto, Vice President of Marketing, join Cardiac Insight’s team to support growth and accelerate market adoption

Confusion regarding the COVID-19 vaccination is growing among patients and caregivers coping with Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy. The GBS|CIDP Foundation International provides up-to-date resources, publications and statements that are vetted through the Foundation’s Global Medica

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Peter Arduini, president and chief executive officer will present virtually at the 39 th Annual J.P. Morgan Healthcare conference on January 14, 2021 at 8:20am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at http://investor.integralife.com/events-and

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 66,000 shares of the common stock of the Company to 5 newly hired non-officer employees, with a per share exercise price of $17.78, the closing trading price on the grant date. The stock options were granted pursu

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the pu

Atomwise, the leader in using artificial intelligence for small-molecule drug discovery, unveiled its growing portfolio of emerging joint venture companies with research programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders.